374 related articles for article (PubMed ID: 35163370)
21. Pheochromocytoma: an update on genetics and management.
Karagiannis A; Mikhailidis DP; Athyros VG; Harsoulis F
Endocr Relat Cancer; 2007 Dec; 14(4):935-56. PubMed ID: 18045948
[TBL] [Abstract][Full Text] [Related]
22. Molecular markers of paragangliomas/pheochromocytomas.
Zhikrivetskaya SO; Snezhkina AV; Zaretsky AR; Alekseev BY; Pokrovsky AV; Golovyuk AL; Melnikova NV; Stepanov OA; Kalinin DV; Moskalev AA; Krasnov GS; Dmitriev AA; Kudryavtseva AV
Oncotarget; 2017 Apr; 8(15):25756-25782. PubMed ID: 28187001
[TBL] [Abstract][Full Text] [Related]
23. Malignant pheochromocytomas and paragangliomas: molecular signaling pathways and emerging therapies.
Santarpia L; Habra MA; Jiménez C
Horm Metab Res; 2009 Sep; 41(9):680-6. PubMed ID: 19343618
[TBL] [Abstract][Full Text] [Related]
24. Molecular genetic alterations in adrenal and extra-adrenal pheochromocytomas and paragangliomas.
Dannenberg H; Komminoth P; Dinjens WN; Speel EJ; de Krijger RR
Endocr Pathol; 2003; 14(4):329-50. PubMed ID: 14739490
[TBL] [Abstract][Full Text] [Related]
25. Metastatic sympathetic paraganglioma in a patient with loss of the SDHC gene.
Rich T; Jackson M; Roman-Gonzalez A; Shah K; Cote GJ; Jimenez C
Fam Cancer; 2015 Dec; 14(4):615-9. PubMed ID: 26162468
[TBL] [Abstract][Full Text] [Related]
26. Molecular imaging and theranostic approaches in pheochromocytoma and paraganglioma.
Taïeb D; Pacak K
Cell Tissue Res; 2018 May; 372(2):393-401. PubMed ID: 29450723
[TBL] [Abstract][Full Text] [Related]
27. The Pheochromocytoma/Paraganglioma syndrome: an overview on mechanisms, diagnosis and management.
Lima JV; Kater CE
Int Braz J Urol; 2023; 49(3):307-319. PubMed ID: 37115176
[TBL] [Abstract][Full Text] [Related]
28. In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas.
Toledo RA; Qin Y; Srikantan S; Morales NP; Li Q; Deng Y; Kim SW; Pereira MA; Toledo SP; Su X; Aguiar RC; Dahia PL
Endocr Relat Cancer; 2013 Jun; 20(3):349-59. PubMed ID: 23533246
[TBL] [Abstract][Full Text] [Related]
29. [Pediatric pheochromocytoma and paraganglioma: an update].
Garnier S; Réguerre Y; Orbach D; Brugières L; Kalfa N
Bull Cancer; 2014 Oct; 101(10):966-75. PubMed ID: 25373696
[TBL] [Abstract][Full Text] [Related]
30. Screening of mutations in genes that predispose to hereditary paragangliomas and pheochromocytomas.
Lefebvre S; Borson-Chazot F; Boutry-Kryza N; Wion N; Schillo F; Peix JL; Brunaud L; Finat A; Calender A; Giraud S
Horm Metab Res; 2012 May; 44(5):334-8. PubMed ID: 22517554
[TBL] [Abstract][Full Text] [Related]
31. Emerging molecular markers of metastatic pheochromocytomas and paragangliomas.
Goncalves J; Lussey-Lepoutre C; Favier J; Gimenez-Roqueplo AP; Castro-Vega LJ
Ann Endocrinol (Paris); 2019 Jun; 80(3):159-162. PubMed ID: 31053249
[TBL] [Abstract][Full Text] [Related]
32. Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas.
Welander J; Söderkvist P; Gimm O
Endocr Relat Cancer; 2011 Dec; 18(6):R253-76. PubMed ID: 22041710
[TBL] [Abstract][Full Text] [Related]
33. Pheochromocytoma/Paraganglioma: Is This a Genetic Disorder?
Fishbein L
Curr Cardiol Rep; 2019 Jul; 21(9):104. PubMed ID: 31367972
[TBL] [Abstract][Full Text] [Related]
34. Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients.
Currás-Freixes M; Inglada-Pérez L; Mancikova V; Montero-Conde C; Letón R; Comino-Méndez I; Apellániz-Ruiz M; Sánchez-Barroso L; Aguirre Sánchez-Covisa M; Alcázar V; Aller J; Álvarez-Escolá C; Andía-Melero VM; Azriel-Mira S; Calatayud-Gutiérrez M; Díaz JÁ; Díez-Hernández A; Lamas-Oliveira C; Marazuela M; Matias-Guiu X; Meoro-Avilés A; Patiño-García A; Pedrinaci S; Riesco-Eizaguirre G; Sábado-Álvarez C; Sáez-Villaverde R; Sainz de Los Terreros A; Sanz Guadarrama Ó; Sastre-Marcos J; Scolá-Yurrita B; Segura-Huerta Á; Serrano-Corredor Mde L; Villar-Vicente MR; Rodríguez-Antona C; Korpershoek E; Cascón A; Robledo M
J Med Genet; 2015 Oct; 52(10):647-56. PubMed ID: 26269449
[TBL] [Abstract][Full Text] [Related]
35. Pheochromocytomas and paragangliomas.
Yen K; Lodish M
Curr Opin Pediatr; 2021 Aug; 33(4):430-435. PubMed ID: 34039901
[TBL] [Abstract][Full Text] [Related]
36. Update on the management of unusual neuroendocrine tumors: pheochromocytoma and paraganglioma, medullary thyroid cancer and adrenocortical carcinoma.
Strosberg JR
Semin Oncol; 2013 Feb; 40(1):120-33. PubMed ID: 23391119
[TBL] [Abstract][Full Text] [Related]
37. [Pheochromocytomas and paragangliomas: implications of new insights for diagnosis and treatment].
van der Kleij-Corssmit EP; Havekes B; Vriends AH; Jansen JC; Romijn JA
Ned Tijdschr Geneeskd; 2008 Mar; 152(9):489-93. PubMed ID: 18389879
[TBL] [Abstract][Full Text] [Related]
38. Management of pheochromocytomas and paragangliomas: Review of current diagnosis and treatment options.
Eid M; Foukal J; Sochorová D; Tuček Š; Starý K; Kala Z; Mayer J; Němeček R; Trna J; Kunovský L
Cancer Med; 2023 Jul; 12(13):13942-13957. PubMed ID: 37145019
[TBL] [Abstract][Full Text] [Related]
39. An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes.
Gimenez-Roqueplo AP; Dahia PL; Robledo M
Horm Metab Res; 2012 May; 44(5):328-33. PubMed ID: 22328163
[TBL] [Abstract][Full Text] [Related]
40. Epithelial to mesenchymal transition is activated in metastatic pheochromocytomas and paragangliomas caused by SDHB gene mutations.
Loriot C; Burnichon N; Gadessaud N; Vescovo L; Amar L; Libé R; Bertherat J; Plouin PF; Jeunemaitre X; Gimenez-Roqueplo AP; Favier J
J Clin Endocrinol Metab; 2012 Jun; 97(6):E954-62. PubMed ID: 22492777
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
